Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications

Annals of Clinical Psychiatry

Volumn 17, Issue 2, 2005, Pages 83-93

  McIntyre, Roger S ^a,b   Konarski, Jakub Z ^c   Misener, Virginia L ^d   Kennedy, Sidney H ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bipolar disorder; Comorbidity; Diabetes mellitus; Insulin; Mortality

Indexed keywords

ANTIDIABETIC AGENT; CARBAMAZEPINE; CYTOKINE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; LITHIUM CARBONATE; NEUROLEPTIC AGENT; PHOSPHOLIPID; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

BIPOLAR DISORDER; BODY MASS; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; EATING HABIT; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR DEPRESSION; MEDLINE; MORTALITY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING;

EID: 22044436909     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230590932380     Document Type: Review

References (100)

1. Akiskal HS, Bourgeois ML, Angst, J, Post R, Moller, H, and Hirschfeld R: Re-Evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect. Disord. 2000; 59 Suppl 1:S5-S30
2. Judd LL and Akiskal HS: The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 2003; 73(1-2):123-131
3. Tohen M, Strakowski SM, Zarate C Jr., Hennen J, Stoll A.L, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, and Cohen BM: Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am. J. Psychiatry 2000; 157(2):220-228
4. Wyatt RJ and Henter I: An economic evaluation of manic-depressive illness-1991. Soc. Psychiatry. Psychiatr. Epidemiol. 1995; 30(5):213-219
5. Murray, CJ and Lopez AD: Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 5-17-1997; 349(9063):1436-1442
6. Rucci P, Frank E, Kostelnik B, Fagiolini A, Mallinger AG, Swartz HA, Thase ME, Siegel L, Wilson D, and Kupfer DJ, Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy. Am. J. Psychiatry 2002; 159(7):1160-1164
7. Peele, PB, Xu Y, and Kupfer DJ: Insurance expenditures on bipolar disorder: clinical and parity implications. Am. J. Psychiatry 2003; 160(7):1286-1290
8. Osby U Brandt L, Correia N, Ekbom A, and Sparen P: Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 2001; 58(9):844-850
9. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 Suppl 1:S5-S10
10. Musselman DL, Betan E, Larsen H, and Phillips LS: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol. Psychiatry 8-1-2003; 54(3):317-329
11. Angst F, Stassen HH, Clayton PJ., and Angst J: Mortality of Patients with mood disorders: follow-up over 34-38 Years. J. Affect. Disord. 2002; 68(2-3):167-181
12. Keck PE, Buse JB, Dagogo-Jack S, D'Alessio DA, Daniels SR, McElroy SL, McIntyre RS, Sernyak MJ, Wirshing DA, and Wirshing, WC. Metabolic disease and severe mental illness. Post-graduate Medicine Special Report 2003
13. Mukherjee S, Decina P, Bocola V, Saraceni F, and Scapicchio PL: Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 1996; 37(1):68-73
14. Goodnick PJ: Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry 2001; 13(1):31-41
15. Kooy FH: Hyperglycemia in mental disorders. Brain 1919; 42:214-289
16. Braceland FJ, Meduna, LJ, and Vaichulis, JA: Delayed action of insulin in schizophrenia. Am. J. Psychiatry 1945; 102:108-110
17. Mukherjee S, Schnur DB, and Reddy, R: Family history of type 2 diabetes in schizophrenic patients. Lancet 3-4-1989;1(8636):495
18. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D, Sato Y, Suzuki S, and Kongo M: Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49(10):1255-1260
19. McIntyre RS, Mancini DA, and Basile VS: Mechanisms of antipsychotic-induced weight gain. J. Clin. Psychiatry 2001; 62(Suppl 23):23-29
20. Haupt DW, and Newcomer JW: Abnormalities in glucose regulation associated with mental illness and treatment. J. Psychosom. Res. 2002; 53(4):925-933
21. Newcomer JW, Haupt DW, Fucetola R, Melson, AK, Schweiger JA, Cooper BP, and Selke G: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002; 59(4):337-345
22. Shiloah E, Witz S, Abramovitch Y, Cohen O, Buchs A, Ramot Y, Weiss M, Unger A, and Rapoport MJ: Effect of acute psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes Care 2003; 26(5):1462-1467
23. Ryan MC, Collins P, and Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003; 160(2):284-289
24. Rasgon N and Jarvik L: Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J Gerontol. A Biol. Sci. Med Sci. 2004; 59(2):178-183
25. Bushe C and Holt R: Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br. J. Psychiatry Suppl 2004; 47:S67-S71
26. Gildea EF, McLean VL, and Man, EB: Oral and intravenous dextrose tolerance curves of patients with manic-depressive psychosis. Arch. Neurol. Psychiat. 1943; 49:852-859
27. Van der Velde CD and Gordon MW: manic-depressive illness, diabetes mellitus, and lithium carbonate. Arch. Gen. Psychiatry 1969;21:478-485
28. Lilliker SL: Prevalence of diabetes in a manic-depressive population. Compr. Psychiatry 1980; 21(4):270-275
29. Lustman PJ, Griffith LS, Clouse RE, and Cryer PE: Psychiatric illness in diabetes mellitus. Relationship to symptoms and glucose control. J Nerv. Ment. Dis. 1986; 174(12):736-742
30. Cassidy F, Ahearn E, and Carroll BJ: Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am. J. Psychiatry 1999; 156(9):1417-1420
31. Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Paras L, and Miller R: Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr. Bull. 1999; 25(2):321-335
32. Regenold WT, Kling MA, and Hauser P: Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders. Psychoneuroendocrinology 2000; 25(6):593-606
33. Hale PJ, Nattrass M, Silverman, SH, Sennit C, Perkins CM, Uden A, and Sundkvist G: Peripheral nerve concentrations of glucose, fructose, sorbitol and myoinositol in diabetic and non-diabetic patients. Diabetologia 1987; 30(7):464-467
34. Regenold WT, Thapar RK, Marano C, Gavirneni S, and Kondapavuluru PV: Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J. Affect. Disord. 2002; 70(1):19-26
35. Ruzickova M, Slaney C, Garnham J, and Aida M: Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can. J. Psychiatry 2003; 48(7):458-461
36. Kessing LV, Nilsson FM, Siersma V, and Andersen PK: Increased risk of developing diabetes in depressive and bipolar disorders? J. Psychiatr. Res. 2004; 38(4):395-402
37. Nilsson FM, Kessing LV, and Bolwig TG: Increased risk of developing Parkinson's Disease for patients with major affective disorder: a register study. Acta Psychiatr. Scand. 2001; 104(5):380-386
38. Kessing LV and Nilsson FM: Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect. Disord. 2003; 73(3):261-269
39. Silveri F, Brecciaroli D, Argentati F, and Cervini C: Serum levels of insulin in overweight patients with osteoarthritis of the knee. J Rheumatol. 1994; 21(10):1899-1902
40. Sturmer T, Brenner H, Brenner RE, and Gunther KP: Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis. The Ulm Osteoarthritis Study. Scand. J. Rheumatol. 2001; 30(3):169-171
41. Dessein PH, Stanwix AE, and Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: Acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002; 4(5):R5
42. Elmslie JL, Silverstone JT, Mann JI, Williams SM, and Romans SE: Prevalence of overweight and obesity in bipolar patients. J. Clin. Psychiatry 2000; 61(3):179-184
43. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, and Nemeroff, CB: Are mood disorders and obesity related? A review for the mental health professional. J. Clin. Psychiatry 2004; 65(5):634-651
44. Yamamoto H, Nagai K, and Nakagawa H: Additional evidence that the suprachiasmatic nucleus is the center for regulation of insulin secretion and glucose homeostasis. Brain Res. 6-25-1984; 304(2):237-241
45. Ibuka N and Kawamura H: Loss of circadian rhythm in sleep-wakefulness cycle in the rat by suprachiasmatic nucleus lesions. Brain Res. 1975; 96(1):76-8l
46. Reppert SM and Weaver DR: Coordination of circadian timing in mammals. Nature 8-29-2002; 418(6901):935-941
47. Berson DM: Strange vision: Ganglion cells as circadian photoreceptors. Trends Neurosci. 2003; 26(6):314-320
48. Nagai K, Fujii T, Inoue S, Takamura Y, and Nakagawa H: Electrical stimulation of the suprachiasmatic nucleus of the hypothalamus causes hyperglycemia. Horm. Metab Res 1988; 20(1):37-39
49. Creager MA, Luscher TF, Cosentino F, and Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 9-23-2003; 108(12):1527-1532
50. Luscher TF, Creager MA, Beckman JA, and Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 9-30-2003; 108(13):1655-1661
51. Ferguson SC, Blane A, Perros P, McCrimmon RJ, Best JJ, Wardlaw J, Deary IJ, and Frier BM: Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 2003; 52(1):149-156
52. Brands AM, Kessels RP, de Haan EH, Kappelle LJ, and Biessels GJ: Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur. J. Pharmacol 4-19-2004; 490(1-3):159-168
53. Ahearn EP, Steffens DC, Cassidy F, Van Meter SA, Provenzale JM, Seldin MF, Weisler RH, and Krishnan KR: Familial Leukoencephalopathy in bipolar disorder. Am. J. Psychiatry 1998; 155(11):1605-1607
54. Bearden CE, Hoffman KM, and Cannon TD: The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar. Disord. 2001; 3(3):106-150
55. Moore PB, Shepherd DJ, Eccleston D, Macmillan IC, Goswami U, McAllister VL, and Ferner IN: Cerebral white matter lesions in bipolar affective disorder: relationship to outcome. Br. J. Psychiatry 2001; 178:172-176
56. Ziedonis D, Williams JM, and Smelson D: Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am. J Med Sci. 2003; 326(4):223-230
57. Watson S, Gallagher P, Ritchie JC, Ferrier IN, and Young AH: Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br. J. Psychiatry 2004; 184:496-502
58. Rybakowski JK, and Twardowska K: The dexamethasone/corticotropin- releasing hormone test in depression in bipolar and unipolar affective illness. J. Psychiatr. Res. 1999; 33(5):363-370
59. Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, and Heuser IJ: Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol. Psychiatry 12-15-1995; 38(12):797-802
60. Dantzer R: Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun. 2001; 15(1):7-24
61. Kronfol Z: Immune dysregulation in major depression: a critical review of existing evidence. Int. J. Neuropsychopharmacol. 2002; 5(4):333-343
62. Hornig M, Goodman DB, Kamoun M, and Amsterdam JD: Positive and negative acute phase proteins in affective subtypes. J Affect. Disord. 1998; 49(1):9-18
63. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, and Leu SJ: Immunologic variables in acute mania of bipolar disorder. J. Neuroimmunol. 2004; 150(1-2):116-122
64. Maes M, Bosmans E, Calabrese J, Smith R, and Meltzer HY: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995; 29(2):141-152
65. Tsai SY, Chen KP, Yang YY, Chen CC, Lee JC, Singh VK, and Leu SJ: Activation of indices of cell-mediated immunity in bipolar mania. Biol. Psychiatry 4-15-1999; 45(8):989-994
66. Tsai SY, Yang YY, Kuo CJ, Chen CC, and Leu SJ: Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect. Disord. 2001; 64(2-3): 185-193
67. Breunis MN, Kupka RW, Nolen WA, Suppes T, Denicoff KD, Leverich GS, Post RM, and Drexhage HA: High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry 1-15-2003; 53(2):157-165
68. Greenberg AS and McDaniel ML: Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. European Journal of Clinical Investigation 2002; 32(Suppl. 3):24-34
69. Grimble RF: Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab Care 2002; 5(5):551-559
70. Pickup JC and Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41(10): 1241-1248
71. Donath MY, Storling J, Maedler K, and Mandrup-Poulsen T: Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 2003; 81(8):455-470
72. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, and Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab 2002; 87(5):2084-2089
73. Kern PA, Ranganathan S, Li C, Wood L, and Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol Endocrinol. Metab 2001; 280(5):E745-E751
74. Sadeghi HM, Schnelle JF, Thoma JK, Nishanian P, and Fahey JL: Phenotypic and functional characteristics of circulating monocytes of elderly persons. Exp. Gerontol. 1999; 34(8):959-970
75. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, and De Benedictis G: Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000; 908:244-254
76. Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, Carella C, Giugliano D, Varricchio M, and D'Onofrio F: Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am. J. Physiol 1998; 275(2 Pt 1):E294-E299
77. Stoll AL, Renshaw PF, Yurgelun-Todd DA, and Cohen BM: Neuroimaging in bipolar disorder: What have we learned? Biol. Psychiatry 9-15-2000; 48(6):505-517
78. Duelli R and Kuschinsky W: Brain glucose transporters: relationship to local energy demand. News Physiol Sci. 2001; 16:71-76
79. McEwen BS, Magarinos AM, and Reagan LP: Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J. Psychosom. Res. 2002; 53(4):883-890
80. Wood IS and Trayhurn P: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr. 2003; 89(1):3-9
81. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P, and Baron AD: Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J. Clin. Invest 6-1-1998; 101(11):2377-2386
82. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, and Shulman GI: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N. Engl. J. Med. 7-22-1999; 341(4):240-246
83. Shepherd PR and Kahn BB: Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N. Engl. J. Med. 7-22-1999; 341(4):248-257
84. Gould TD, Zarate CA, and Manji HK: Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J. Clin. Psychiatry 2004; 65(1):10-21
85. Cohrn P, and Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2(10):769-776
86. Lenox RH, Gould TD, and Manji HK: Endophenotypes in bipolar disorder. Am. J Med. Genet. 5-8-2002; 114(4):391-406
87. Horrobin DF and Bennett CN: Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot. Essent. Fatty Acids 1999; 60(4):217-234
88. Rapoport SI and Bosetti F: Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 2002; 59(7):592-596
89. Florez JC, Hirschhorn J, and Altshuler D: The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet. 2003; 4:257-291
90. Baron M: Manic-depression genes and the new millennium: poised for discovery. Mol. Psychiatry 2002; 7(4):342-358
91. Craddock N, Dave S, and Greening J: Association studies of bipolar disorder. Bipolar. Disord. 2001; 3(6):284-298
92. Chiba M, Suzuki S, Hinokio Y, Hirai M, Satoh Y, Tashiro A, Utsumi A, Awata T, Kongo M, and Toyota T: Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49(9):1145-1149
93. Cryns K, Sivakumaran TA, Van den Ouweland JM, Pennings, RJ, Cremers CW, Flothmann K, Young TL, Smith RJ, Lesperance MM, and Van Camp G: Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum. Mutat. 2003; 22(4):275-287
94. Swift M and Swift RG: Psychiatric disorders and mutations at the Wolfram syndrome locus. Biol. Psychiatry 5-1-2000; 47(9):787-793
95. Kawamoto T, Horikawa Y, Tanaka T, Kabe N, Takeda J, and Mikuni M: Genetic variations in the WFS1 gene in Japanese with type 2 diabetes and bipolar disorder. Mol. Genet. Metab 2004; 82(3):238-245
96. Reaven GM: Banting Lecture 1988. Role of Insulin resistance in human disease. Diabetes 1988; 37(12):1595-1607
97. Kato MM, Currier MB, Gomez CM, Hall L, and Gonzalez-Blanco M: Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim. Care Companion. J Clin. Psychiatry 2004; 6(2):74-77
98. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl 1:S11-S14
99. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, and Baldessarini RJ: Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am. J. Psychiatry 2000; 157(2):179-184
100. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, and Altshuler L: Management of Bipolar disorder during pregnancy and the post-partum period. Am. J. Psychiatry 2004; 161(4):608-620